CD Protein Inhibitors 

  Products    Products    Diseases    News 


«12...7071727374757677787980...39323933»
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Journal:  Pembrolizumab related perforated appendicitis. (Pubmed Central) -  Aug 3, 2024   
    Disease control achieved with this protocol did not differ significantly between elderly and younger patients but had acceptable tolerability, demonstrating its benefit even in elderly LA-NSCLC patients aged 75 years or above. In patients who develop acute abdominal pain with or without diarrhea during immunotherapy, urgent imaging, endoscopic and clinical evaluation should be performed, and bowel perforation, although rare, should be considered as a potential complication of any immunotherapy.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Journal, Metastases:  Proton pump inhibitors decrease efficacy of palbociclib in patients with metastatic breast. (Pubmed Central) -  Aug 3, 2024   
    This study demonstrates that the concurrent use of PPIs in mBC patients receiving palbociclib negatively affects PFS, particularly in the first-line setting. Nevertheless, further investigation is warranted to explore the impact of PPIs on cycle-dependent kinase 4/6 inhibitors.
  • ||||||||||  Rituxan (rituximab) / Roche
    Journal:  Transplantation in Adult Patients with Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis: Yes or No? (Pubmed Central) -  Aug 2, 2024   
    Patients with EBV infection to B cells could benefit from rituximab, whereas lethal outcomes may occur in patients with EBV infection to T cells, nature killer (NK) cells, or multilineages...For patients who achieved PR after initial treatment, HSCT was recommended. A wait-and-see strategy could be adopted for patients who achieved CR after initial treatment, but with the risk of failing to achieve a second CR.
  • ||||||||||  Epidaza (chidamide) / Chipscreen, AiRuiKa (camrelizumab) / HLB Bio Group, CART-30 / AbelZeta Pharma
    Biomarker, Journal, Tumor microenvironment:  Epigenetic agents plus anti-PD-1 reshapes tumor microenvironment and restores antitumor efficacy in Hodgkin lymphoma. (Pubmed Central) -  Aug 2, 2024   
    P2
    In this study, we evaluated the efficacy and safety of a triplet regimen consisting of the histone deacetylase inhibitor chidamide, decitabine and anti-PD-1 camrelizumab (CDP) in 52 patients with relapsed/refractory cHL who had previously received DP therapy (NCT04233294)...The classical CD30+ HRS-like cells interacted with the abundant immunosuppressive IL21+CD4+ T helper cells, forming a positive feedback loop that supported their survival...CDP treatment promoted the activation of diverse tumor-reactive CD8+ T cells and suppressed the proliferation of IL21+CD4+ T cells by inhibiting STAT1/3 signaling, thereby alleviating their immunosuppressive effects. These findings provide insights into the cHL microenvironment that contributes to anti-PD-1 resistance and highlight the therapeutic effectiveness of dual epi-immunotherapy in overcoming immunotherapy resistance.
  • ||||||||||  Tecartus (brexucabtagene autoleucel) / Gilead, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
    Journal:  Impact of Prior Inotuzumab Ozogamicin Treatment on Brexucabtagene Autoleucel outcomes in Adults with B-cell ALL. (Pubmed Central) -  Aug 2, 2024   
    In conclusion, while InO exposure was associated with inferior survival outcomes following brexu-cel in unadjusted analyses, these associations were no longer significant in multivariate analyses, suggesting it is unlikely that InO negatively impacts brexu-cel efficacy. Our data instead imply that InO-exposed recipients of brexu-cel tend to be higher-risk patients with intrinsic adverse leukemia biology.
  • ||||||||||  Ocrevus (ocrelizumab) / Roche
    Journal, HEOR:  The Cost-Utility analysis of adding ocrelizumab to the treatment plan for primary progressive multiple sclerosis in Iran. (Pubmed Central) -  Aug 2, 2024   
    While adding ocrelizumab is not a cost-effective strategy at the threshold of one-time GDP per capita, its substantial clinical benefits should not be overlooked. Therefore, the importance of formulating healthcare policies regarding the use of high-cost medications like ocrelizumab, including budget allocation, resource distribution, and potential shifts in healthcare priorities, has become more crucial than ever.
  • ||||||||||  Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
    Review, Journal:  Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions. (Pubmed Central) -  Aug 2, 2024   
    Veno-occlusive disease/sinusoidal obstruction syndrome is a potential complication of InO treatment, particularly when followed by HSCT. Herein, the authors review the historical development and current status of InO, strategies for mitigating the risk of InO-related veno-occlusive disease/sinusoidal obstruction syndrome, and future directions for InO research and clinical use.
  • ||||||||||  Rituxan (rituximab) / Roche
    Journal:  Severe haematological involvement in children with systemic lupus erythematosus and clinical associations. (Pubmed Central) -  Aug 2, 2024   
    Severe haematological indices at onset are common but not related with disease outcomes. Prevention of flares is important to improve outcomes, and a more rigorous maintenance strategy would benefit most to children who display haematological indices refractory to conventional immunosuppressants and those with anti-cardiolipin antibodies.
  • ||||||||||  Retrospective data, Journal, Metastases:  Persistence of advanced systemic pharmacological treatment of moderate-to-severe psoriasis among bio-na (Pubmed Central) -  Aug 2, 2024   
    Furthermore, these treatments demonstrated lower rates of discontinuation compared to other study drugs included in the analysis. Understanding the balance between efficacy and feasibility in treatment decisions is crucial, as feasibility may impact persistency outcomes and potentially increase persistency rates.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS
    Review, Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker:  Immune checkpoint inhibitors targeting PD-1/PD-L1 in the treatment of human lymphomas. (Pubmed Central) -  Aug 2, 2024   
    Combination strategies incorporating ICIs with conventional chemotherapy or targeted agents show enhanced efficacy and are being explored extensively. In this review we discuss the most important features of the tumor microenvironment of NHLs and cHLs, address the therapeutic approaches with ICIs and try to outline future perspectives.
  • ||||||||||  Rituxan (rituximab) / Roche
    Journal:  Association between skeletal muscle mass and treatment response in patients with diffuse large B-cell lymphoma. (Pubmed Central) -  Aug 2, 2024   
    In addition, patients with low SMM were more likely to receive R-CHOP-like treatment (21.2% vs. 7%, p?=?0.022) and experienced more delays in administration (42.9% vs. 33.3%, p?=?0.452)...An interesting result was the interaction of low SMM with hypertension as a risk factor for not achieving CR (HR 2.7; 95% CI [1.1-6.5] p?=?0.034) or OS (HR 7.9; 95% CI [3.4-18.8] p?<?0.001). Low SMM was not a risk factor for achieving CR in patients with DLBCL and seemed to play a role in OS.
  • ||||||||||  Tecvayli (teclistamab-cqyv) / Genmab, J&J
    Journal:  Safety outcomes of teclistamab accelerated dose escalation. (Pubmed Central) -  Aug 2, 2024   
    These findings may support outpatient administration for teclistamab. Accelerated dose escalation strategy allowed for the optimization of hospitalization and resources.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Trial primary completion date, Minimal residual disease:  Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL (clinicaltrials.gov) -  Aug 2, 2024   
    P2,  N=2, Active, not recruiting, 
    No abstract available Trial primary completion date: Jun 2024 --> Jun 2025
  • ||||||||||  Gazyva (obinutuzumab) / Roche, Biogen, Calquence (acalabrutinib) / AstraZeneca
    Trial completion date, Trial primary completion date, Combination therapy:  Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia (clinicaltrials.gov) -  Aug 2, 2024   
    P2,  N=60, Recruiting, 
    Trial primary completion date: Jun 2024 --> Jun 2025 Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
  • ||||||||||  IO-202 - Immune / Onc Therap
    Enrollment closed, Monotherapy:  IO-202-CL-001: IO-202 as Monotherapy and IO-202 Plus Azacitidine  (clinicaltrials.gov) -  Aug 2, 2024   
    P1,  N=106, Active, not recruiting, 
    Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Biomarker, Journal, Next-generation sequencing, PD(L)-1 Biomarker, IO biomarker, Metastases:  Utility of next-generation sequencing in the diagnosis of metastatic melanoma: A case report. (Pubmed Central) -  Aug 2, 2024   
    This case emphasizes the importance of molecular studies for definitive diagnosis in challenging clinical situations, especially when there is discordance among histopathological, immunohistochemical, and molecular studies. Integration of clinical, histopathological, and molecular features is warranted.
  • ||||||||||  Verzenio (abemaciclib) / Eli Lilly
    Trial completion date, Trial primary completion date:  Study of Abemaciclib in Dedifferentiated Liposarcoma (clinicaltrials.gov) -  Aug 2, 2024   
    P2,  N=33, Active, not recruiting, 
    Trial completion date: Aug 2027 --> Feb 2027 | Trial primary completion date: Jan 2026 --> Jul 2025 Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025